The State of Supplement Claims · Category report
We ruled the 368 best-selling joint listings on Amazon US, from 194 brands, against all 109 published standards. 73% fail. 37% of the brands carry at least one Critical finding. The category’s signature is the promise: pain relief, which is a drug claim, at 34 brands, and “works in [X] days” at 25. 72 of the 194 brands carry a Critical claim, the class that can get a listing suppressed, on listings that were selling when we read them.
Method · every phrase ruled against FDA structure/function, FTC substantiation and marketplace policy · 109 standards, v1.4.1 · scanned 14-27 Sep 2026 · brands never named in public data · free to cite with attribution
Executive summary
Seven in ten joint listings fail.
267 of the 368 listings received a FAIL verdict, 73% against 76% across all eight categories. 21 listings, 6%, pass with nothing to fix. These are the bestsellers: glucosamine, collagen, turmeric and the blends built around them.
The most common Critical claim is pain relief.
“Analgesic”, “pain reliever” and “relieves pain” appear at 34 of 194 brands. Relieving pain is the defining claim of a drug, so on a supplement it is an implied drug claim and Critical every time. “Heals” follows at 14, and “reverses” at 6: treatment verbs, Critical every time.
The category sells on a deadline it cannot prove.
“Works in [X] days” at 25 brands is a proof claim: a promise of an outcome on a schedule, with no evidence on the listing. It is a High finding and it is the FTC’s territory.
Joint copy is written for someone in pain who wants a date: relief, in seven days. Relief is a drug’s claim, and a date is a promise nobody on the listing can keep.
Method and data
Listings enter the database through the same engine that runs our paid audits. Each listing is ruled, phrase by phrase, against all 109 standards in force at the scan, built on FDA structure/function rules, FTC substantiation guidance and Amazon’s supplement claims policy. Every finding must quote the page word for word, and any quote the software cannot find on the page is discarded before it enters published figures. Since 28 Sep 2026 the category also holds every ruled listing from Amazon’s own Best Sellers lists for it. Paid audit verdicts are signed by a licensed pharmacist. Individual brands are never named in public data. The full method and the standards behind it are documented on the Standards page.
The whole-database figures this report is drawn against are in The State of Supplement Claims; the category’s screenshot-ready numbers are on its scorecard.
The verdict split
A FAIL verdict means the listing carries at least one Critical or High finding, a phrase that breaks a published standard seriously enough that the listing as a whole does not pass. FIX THEN PASS means the only findings were Medium or Low. PASS means no findings at all.
Every ruled joint listing by verdict · 368 listings
21 of 368 listings pass with nothing to fix. A FAIL verdict does not mean the product is unsafe or ineffective; this report measures marketing language, not chemistry. But marketing language is what regulators, platforms and courts read, and by that measure 73% of the category’s bestsellers do not hold up.
Percentages rounded to the nearest point. Counts are exact.
Fail rate by category
Joint sits below the average on fail rate and near it on the share of brands carrying a Critical finding. Its pass count, 21 of 368, is among the better ones we scan.
The right-hand column is the share of that category’s brands carrying at least one Critical finding. Rows count every listing ruled in that category; a listing sold into two categories is ruled in each.
Fail means at least one Critical or High finding on the live listing.
The phrase table
Ranked by how many of the 194 brands carry each one. Struck phrases are quoted from live listings. The brands are not named. Their copy names them.
Counts are distinct brands, among the 194 ruled in the category, that carry the phrase or a direct variant. Bars are scaled to the top row.
Six of the ten are the paperwork and default-vocabulary failures found across the whole database. The joint-specific rows are a promise, “works in [X] days” (25 brands), a claim drifting in from another category, “boosts immunity” (27), and the one Critical row in the top ten, pain relief (34).
What passes
The same benefits, said the way the passing best sellers say them. Each phrasing below sits on the best-selling listings of at least three brands, on a line with no Critical or High finding, and no finding in the category quotes it. Each one carries the benefit a shopper is looking for without the wording a platform’s review can flag.
Counts are distinct brands, among the 194 ruled in the category, that use the phrasing on a line with no Critical or High finding. Phrasings that differ only in “your”, “the” or the form of the verb are counted together. A phrasing that passes here can still fail beside a disease word, so the line around it matters too.
The same benefit, worded twice. The struck line is quoted from live listings in the category and breaks the standard linked beside it. The line above it carries the same benefit on passing listings, without the claim that can get a listing suppressed.
Say “supports immune function” 3 brands, on passing lines
Not “immune booster” 18 brands · CV-ID-07 High
Say “support healthy inflammatory response” 4 brands, on passing lines
Not “complements anti-inflammatory antioxidant supplement” 4 brands · CV-ID-01 High
Struck lines are lowercased and quoted without the brands that carry them. Passing means no finding against the 109 published standards; it is not a ruling on any one listing, which is read in context.
The claims that can end a listing
Every Critical finding in the category, grouped by the rule it breaks and counted by brand. Joint’s Critical claims lead with the implied drug claim, then a treatment verb, then a false safety status.
Counts are distinct brands with at least one Critical finding of that class. A brand can appear in more than one row.
Inside the findings
Across the 368 listings we logged 1,775 findings. 163 are Critical, 9% of the category’s findings against 9% across the database, with 485 High findings behind them.
Every finding logged in the category, by severity · 1,775 findings
The dated record
The numbers above would matter less if enforcement were theoretical. It is not, and pain and arthritis claims are a long-standing FTC and FDA target.
Four institutions with four different incentives read supplement listings the same way, and the platforms read with machines that keep getting better: Amazon’s AI scans billions of listing changes a day, and Google’s Gemini models read what an ad means. A joint listing that says “relieves pain” is not hiding from any of them.
Sources: FTC penalty schedule and Notice of Penalty Offenses, FDA warning-letter database, Amazon seller policy, public litigation record.
Guidance
This is general information, not legal advice. The data does suggest a clear order of operations.
Never promise relief.
“Pain relief”, “analgesic” and “relieves” are drug claims, at 34 of 194 brands here. “Supports joint comfort and mobility” and “helps maintain healthy cartilage” are the structure/function forms.
Drop the deadline.
“Works in [X] days” (25 brands) is a proof claim the FTC expects evidence for. A money-back policy is fine; a promised outcome on a schedule is not.
Heal and reverse are treatment verbs.
“Heals” is on 14 listings and “reverses” on 6. “Occasional joint stiffness” and “supports joint comfort” are the structure/function territory.
Fix the paperwork.
A Non-GMO claim has no document behind it at 94 brands, the FDA disclaimer is missing at 99, “GMP certified” cannot be verified from the listing at 67, and at 13 brands a stated amount does not match the Supplement Facts panel.
Pharmacist-in-the-loop
Is your joint listing in this data?
Paste the listing and see its findings and its rank in the category, free. The audit answers in five business days: every claim, every channel, pharmacist signed.
Cite this report
Claims Verified, The State of Supplement Claims: Joint, Q3 2026
Free to reproduce with attribution. Every figure on this page is recomputed from the database before each release; the method and the standards are published and versioned.
audit@claimsverified.org →Media and methodology questions: audit@claimsverified.org · © 2026 Claims Verified · Data from the claims database, snapshot 27 Sep 2026 · Reproduction with attribution permitted · Cite as “Claims Verified, The State of Supplement Claims: Joint, Q3 2026” · Not legal advice
See where your own listing sits. One Amazon listing or your website, checked free. No call, no account.
Check my listingSay the most the rules allow. Then keep selling it, everywhere, at any spend.
Clean copy can run on every channel at once with nothing for a machine to switch off, so you can push budget knowing what a reviewer can find. And it is the brand a careful shopper can believe.